Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Clin Transplant ; 38(5): e15322, 2024 May.
Article in English | MEDLINE | ID: mdl-38678589

ABSTRACT

INTRODUCTION: The causal relationship between hyperparathyroidism and kidney graft dysfunction remains inconclusive. Applying Bradford-Hill's temporality and consistency causation principles, we assessed the effect of parathyroid hormone (iPTH) on graft histology and eGFR trajectory on kidney transplant recipients (KTRs) with normal time-zero graft biopsies. METHODS: Retrospective cohort study evaluating the effect of hyperparathyroidism on interstitial fibrosis and tubular atrophy (IF/TA) development in 1232 graft biopsies. Pre-transplant hyperparathyroidism was categorized by KDIGO or KDOQI criteria, and post-transplant hyperparathyroidism by iPTH >1× and >2× the URL 1 year after transplantation. RESULTS: We included 325 KTRs (56% female, age 38 ± 13 years, follow-up 4.2 years [IQR: 2.7-5.8]). Based on pre-transplant iPTH levels, 26% and 66% exceeded the KDIGO and KDOQI targets, respectively. There were no significant differences in the development of >25% IF/TA between KTRs with pre-transplant iPTH levels above and within target range according to KDIGO (53% vs. 62%, P = .16, HR.94 [95% CI:.67-1.32]) and KDOQI (60% vs. 60%, P = 1.0, HR 1.19 [95% CI:.88-1.60]) criteria. Similarly, there were no differences when using 1 year post-transplant iPTH cut-offs > 88 pg/mL (58% vs. 64%, P = .33) and > 176 pg/mL (55% vs. 62%, P = .19). After adjusting for confounders, no significant differences were observed in eGFR trajectories among the iPTH strata. CONCLUSION: In young KTRs who received a healthy graft, no association was found between increased pre- and post-transplant iPTH levels and graft dysfunction, as assessed histologically and through eGFR trajectory. The concept of hyperparathyroidism as a risk factor for graft dysfunction in recipients at low risk requires reevaluation.


Subject(s)
Allografts , Glomerular Filtration Rate , Graft Rejection , Graft Survival , Hyperparathyroidism , Kidney Transplantation , Postoperative Complications , Humans , Kidney Transplantation/adverse effects , Female , Male , Retrospective Studies , Adult , Follow-Up Studies , Hyperparathyroidism/etiology , Hyperparathyroidism/pathology , Prognosis , Risk Factors , Graft Rejection/etiology , Graft Rejection/pathology , Allografts/pathology , Postoperative Complications/etiology , Kidney Function Tests , Kidney Failure, Chronic/surgery , Middle Aged , Parathyroid Hormone/blood
2.
Rev Invest Clin ; 63(6): 558-63, 2011.
Article in English | MEDLINE | ID: mdl-23650668

ABSTRACT

OBJECTIVE: To assess the presence of emotional distress in patients with chronic kidney disease (CKD), and the effect of kidney transplant on these symptoms. MATERIAL AND METHODS: This was a two-part study. Part one was cross-sectional, observational, and descriptive, where 75 patients with CKD were evaluated for emotional distress with the Hospital Anxiety and Depression Scale (HAD) and the Symptom Checklist 90 (SCL-90). In part two, we longitudinally followed 19% of the study cohort to examine symptomatological changes after their kidney transplantation. RESULTS: The results of the HAD indicated that 30.7% of the study cohort with End-Stage Renal Disease (ESRD) showed anxious symptoms, and 25.3% showed depressive symptoms. The change in the HAD total score before and after kidney transplant was not significant. However, a significant decrease in total score on the SCL-90 was observed before and after transplantation. CONCLUSION: Improvement on emotional distress was found after kidney transplantation.


Subject(s)
Kidney Failure, Chronic/psychology , Kidney Transplantation/psychology , Stress, Psychological/diagnosis , Adult , Anemia/complications , Anemia/psychology , Anxiety Disorders/diagnosis , Anxiety Disorders/etiology , Anxiety Disorders/psychology , Checklist , Cross-Sectional Studies , Depressive Disorder/diagnosis , Depressive Disorder/etiology , Depressive Disorder/psychology , Female , Follow-Up Studies , Humans , Hypertension/complications , Hypertension/psychology , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/surgery , Kidney Failure, Chronic/therapy , Male , Mexico , Middle Aged , Peritoneal Dialysis/psychology , Prospective Studies , Renal Dialysis/psychology , Severity of Illness Index , Stress, Psychological/etiology , Stress, Psychological/psychology , Symptom Assessment , Young Adult
3.
Clin Transpl ; : 363-7, 2010.
Article in English | MEDLINE | ID: mdl-21696054

ABSTRACT

Highly sensitized patients represent a challenge in all transplant programs. The use of bortezomib in combination with other strategies could be a real option for some patients. Unfortunately, one single cycle of four doses of bortezomib with 3 PP sessions may not be sufficient. With all the agents available to use in desensitization it is still not clear what is the best combination or who are the best candidates. We need more time and experience with its use to identify which patients could be the best candidate to receive it for desensitization.


Subject(s)
Boronic Acids/therapeutic use , Immunosuppressive Agents/therapeutic use , Kidney Transplantation , Protease Inhibitors/therapeutic use , Pyrazines/therapeutic use , Tissue Donors/supply & distribution , Waiting Lists , Adult , Bortezomib , Down-Regulation , Female , Graft Survival/drug effects , HLA Antigens/immunology , Humans , Isoantibodies/blood , Kidney Transplantation/immunology , Male , Mexico , Middle Aged , Patient Selection , Plasmapheresis , Proteasome Endopeptidase Complex/metabolism , Proteasome Inhibitors , Time Factors , Treatment Outcome
4.
Clin Transpl ; : 153-64, 2009.
Article in English | MEDLINE | ID: mdl-20524282

ABSTRACT

This is a retrospective study that includes four decades of kidney transplant program at our Institute, with a total of 923 kidney transplants in 872 recipients. In this report, the effect of variables in recipient, donor, and transplant on long-term graft survival was analyzed using the Kaplan Meier method with log-rank test for survival comparisons. Global graft survival at our center-analyzed by censoring for death-with-functioning-graft-for 1, 5 and 10 years was 93%, 83% and 74%, respectively, with median survival of 24.5 years. When analyzed for all-cause graft loss, 1, 5 and 10 year survival was 90%, 76% and 61%, with 12.8-year median survival. Variables associated with lower graft survival censored for death-with-functioning-graft were transplantation in an earlier decade, less histocompatibility, younger kidney transplant recipients, no induction therapy, and double drug initial immunosuppression. After Cox's regression multivariate analysis, the risk factors that remained associated with worse survival were younger recipient, earlier transplant decade, and deceased donor.


Subject(s)
Kidney Transplantation/statistics & numerical data , Cadaver , Female , Follow-Up Studies , Graft Survival , HLA Antigens/immunology , Histocompatibility Testing , Humans , Kidney Transplantation/immunology , Kidney Transplantation/mortality , Living Donors , Male , Medical Staff, Hospital/statistics & numerical data , Mexico , Retrospective Studies , Survival Rate , Time Factors , Tissue Donors
5.
Clin Transpl ; : 369-76, 2009.
Article in English | MEDLINE | ID: mdl-20524300

ABSTRACT

The use of bortezomib as a treatment modality of AHR improved and stabilized graft function (clinical response) in the majority of patients. Its use in single dose, even combined with rituximab, does not seem to be useful to obtain a sustained clinical response neither to reduce HLAabs level. The use of 4 doses of bortezomib in days 1, 4, 7, and 10 (1.3 mg/m2 BSA each) plus plasmapheresis produced both a good clinical response and a reduction in DSA. Moving forward, it will necessary to define the long-term effectiveness of bortezomib and whether rituximab administration is indispensable to achieve this goal.


Subject(s)
Boronic Acids/therapeutic use , Graft Rejection/drug therapy , Graft Rejection/immunology , HLA Antigens/immunology , Protease Inhibitors/therapeutic use , Pyrazines/therapeutic use , Adult , Autoantibodies/blood , Biopsy , Bortezomib , Cadaver , Creatinine/blood , Female , Graft Rejection/pathology , Humans , Living Donors , Male , Mexico , T-Lymphocytes/immunology , Tissue Donors , Treatment Outcome
6.
Transplantation ; 86(8): 1111-5, 2008 Oct 27.
Article in English | MEDLINE | ID: mdl-18946350

ABSTRACT

BACKGROUND: Human leukocyte antigen (HLA) antibodies were normally not found in subjects who have not been immunized by pregnancies, transfusions, or transplants. But with new methodology, we now see that HLA antibodies are often found in nonalloimmunized males. METHODS: The sera of 424 healthy male donors were tested with single antigen Luminex beads. RESULTS: Human leukocyte antigen antibodies were detected in 63% of 424 male blood donors when a fluorescent value of more than 1000 was used as the cutoff. Antibodies to class I was found in 42%, class II in 11% and both in 12%. Five males who were tested eight times over a 6-month period consistently had the same specificity at similar strength levels at each testing. The antibodies reacted with specificities that are rare in the general population: 18.9% had antibodies to A*3002; more than 10% had antibodies to A*3101, B76, B*8201, and Cw*1701. About half of the donors with antibodies had one or two specificities; the other half had three or more specificities. Among those with class II specificities, 20.5% had antibodies to DPA1*0201/DPB1*0101, and 10.8% to DQA1*0503/DQB1*0301. Because the above data were obtained by testing sera of 424 Mexican donors, as a check, 29 males in Los Angeles were tested and shown to have similar specificities at roughly similar frequencies. CONCLUSIONS: Normal males were found to have HLA antibodies to infrequent HLA specificities. It is likely that these HLA antibodies are produced to cross-reactive epitopes found in microorganisms, ingested proteins and allergens-making them natural antibodies.


Subject(s)
Antibodies/blood , HLA Antigens/immunology , Adult , Antibody Specificity , Autoantibodies/blood , Cell Line , Humans , Immunosorbent Techniques , Los Angeles , Male , Mexico , Reagent Kits, Diagnostic , Reproducibility of Results , Time Factors
7.
Transpl Immunol ; 18(2): 166-71, 2007 Nov.
Article in English | MEDLINE | ID: mdl-18005863

ABSTRACT

BACKGROUND: Transplant recipients develop antibodies against a wide array of HLA specificities, and not only against the antigens to which they have been exposed. The aim of the present study was to establish if HLA-unrelated immune stimulation is capable of triggering the production of HLA antibodies. METHODS: We determined the presence of HLA antibodies in 20 healthy adults before and after the administration of an immune stimulus (hepatitis B vaccine plus tuberculin skin test). HLA antibodies were assessed with a flow-cytometry based system. RESULTS: At baseline, HBsAg antibodies were detected in protective titers in 75% of the subjects; HLA antibodies were negative in all but one. One week after the antigenic stimulus, HBsAg antibody titers increased significantly, without any detectable changes in HLA antibodies. Surprisingly, HLA antibodies developed in 8 participants one month after the application of the stimulus. One additional subject developed HLA antibodies one month later. Therefore 9/20 subjects became PRA positive during the observation period. Antibody specificities were identified by single antigen assay. The alloantibody response elicited by the immune stimulus was not consistent with memory cell stimulation. CONCLUSIONS: The findings of this study demonstrate that a non-HLA antigenic stimulus is capable of eliciting the development of HLA antibodies in healthy adults.


Subject(s)
Antibodies/immunology , HLA Antigens/immunology , Hepatitis B Vaccines/pharmacology , Adult , Antibody Formation , Antibody Specificity , Female , Flow Cytometry/methods , Hepatitis B Vaccines/immunology , Humans , Isoantibodies/biosynthesis , Isoantibodies/immunology , Male , Middle Aged , Transplantation Immunology , Tuberculin Test
SELECTION OF CITATIONS
SEARCH DETAIL
...